Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)’s stock price has increased by 1.67 compared to its previous closing price of 0.62. However, the company has seen a -8.41% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
Is It Worth Investing in Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Right Now?
LXRX has 36-month beta value of 1.01. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LXRX is 177.07M, and currently, short sellers hold a 24.30% ratio of that float. The average trading volume of LXRX on June 04, 2025 was 15.10M shares.
LXRX’s Market Performance
LXRX stock saw a decrease of -8.41% in the past week, with a monthly decline of -7.14% and a quarterly a decrease of 94.58%. The volatility ratio for the week is 3.58%, and the volatility levels for the last 30 days are 5.91% for Lexicon Pharmaceuticals Inc (LXRX). The simple moving average for the last 20 days is 0.15% for LXRX stock, with a simple moving average of -35.32% for the last 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with Leerink Partners repeating the rating for LXRX by listing it as a “Market Perform.” The predicted price for LXRX in the upcoming period, according to Leerink Partners is $1 based on the research report published on March 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $10. The rating they have provided for LXRX stocks is “Buy” according to the report published on June 17th, 2024.
Leerink Partners gave a rating of “Outperform” to LXRX, setting the target price at $5 in the report published on April 30th of the previous year.
LXRX Trading at 9.13% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.20% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who proposed sale 300,000 shares at the price of $1.60 back on Aug 15 ’24. After this action, COATS LONNEL now owns shares of Lexicon Pharmaceuticals Inc, valued at $480,000 using the latest closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -5.69 for the present operating margin
- 0.98 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -5.68. The total capital return value is set at -0.95. Equity return is now at value -86.09, with -49.60 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -3.98. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -20.18.
Currently, EBITDA for the company is -184.29 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 6.69. The receivables turnover for the company is 0.66for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
To put it simply, Lexicon Pharmaceuticals Inc (LXRX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
